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Abstract
Repurposing or repositioning means validating and application of previously 
approved drugs in the treatment of another disease that might be relevant or irrelevant 
to existing use in disease based on the principle of polypharmacology. Repurposed 
drugs are already well documented for pharmacokinetic, pharmacodynamic, drug 
interaction, and toxicity parameters. In 1962, thalidomide treatment in pregnant 
women led to phocomelia in their newborn but while repurposed based on anti-angio-
genesis property, it showed efficacy in hematologic malignancies like multiple myeloma. 
The repurposing is becoming an essential tool in the anti-cancer drug development 
due to existing drugs are not effective, high cost of treatment, therapy may degrade 
the quality of life, improvement of survival after treatment is not guaranteed, relapse 
may occur, and drug resistance may develop due to tumor heterogeneity. Repurposing 
can be addressed well with the help of literature-based discovery, high throughput 
technology, bioinformatics multi-omics approaches, side effects, and phenotypes. Many 
regulatory bodies like EML, NIH, and FDA promote repurposing programs that support 
the identification of alternative uses of existing medicines. Cancer becomes the major 
health issue, and the need to discover promising anti-cancer drugs through repurposing 
remains very high due to decline in FDA approval since 1990, huge expenses incurred in 
the drug development and prediction of dangerous future burden.
Keywords: repurposing, cancer, bioinformatics, multi-omics, thalidomide tragedy, 
metformin
1. Introduction
1.1 What are the problems?
Cancer is the second deadliest disease after cardiovascular diseases, causing loss 
of billions of lives across the world. Although human kind has developed so many 
anti-cancer medicines, none of them are able to cure the disease. After spending 
of around $650 million for the development in research and development of New 
Chemical Entity (NCE) during time periods of 12–17 years, successful outcome 
compared to standard drugs is less [1]. The success ratio for this NCE in clinical trial 
is less than 10%. Many times, the effects on outcomes like disease free survival, 
quality of life treatment related side effects and complications are discouraging. 
According to ESMO 2019 press release, there was no link between drug cost and 
clinical benefit measured by ESMO-MCBS and the American Society of Clinical 
Oncology Value Framework (ASCO-VF) for various drugs approved for adult solid 
tumor in four European countries and the USA from 2009 to 2017. So, it would 
Drug Repurposing
2
add extra treatment cost to patient therapy. According to Prof. Kerstin Vokinger, 
University of Zurich, Switzerland, and affiliated with the Program on Regulation, 
Therapeutics, and Law (Harvard Medical School, USA), drug pricing should be 
aligned with clinical value [2]. There was drastic decline in average number of FDA 
approved drug since the 1990, but the number of cancer cases rising every year for 
each cancer. So, this imbalance of demand and supply of effective anti-cancer drugs 
can be balanced by implication of drug repurposing [3]. In the oncology medicine, 
the US FDA approved 4 new drugs in 2016 while it was 14 drugs in 2015 and 9 drugs 
in 2014 and 2013 that indicate decrease in anti-cancer drug discovery [4].
1.2 How repurposing can help?
To overcome the problems linked to high expenditures, lengthy and tedious 
research for every NCE with low success in clinical trial, repurposing can help where 
scientists are trying to investigate new therapeutic indication for existing approved 
drugs. Drug repurposing has many advantages in terms of efficient utilization of time 
and money for drug discovery and development processes. The proposed medicines 
for repurposing already have approved pharmaceutical data related to its formulation, 
Pharmacokinetic (absorption, distribution, metabolism and excretion) and pharma-
codynamic profile that collected during preclinical and clinical trial. The proposed 
medicine also passed through much toxicity, side effects testing and passed the phase 
4 of post marketing surveillance so the safety is already established and that reduce the 
chances of drug failure at the end screening process of drug discovery [5]. The repur-
posing can drastically reduce drug discovery time line from 12–17 years to 3–12 years 
due to availability of drug’s pharmacology and pharmaceuticals data [6]. The concept 
of Drug Repurposing is based on validating and application of previously approved 
drug by FDA in the treatment of another disease that might be relevant or irrelevant to 
existing use in disease. The principle of polypharmacology and pleiotropy was work-
ing behind drug repurposing. The anti-cancer drugs receive FDA approval are very 
costliest in recent years that significantly affect pharmacoeconomics of patients. For 
consideration, the cost for a combination-targeted therapy of monoclonal antibodies 
ipilimumab and nivolumab in treatment of metastatic melanoma has been estimated 
to per responder is around $400,000 US [7, 8]. So, all these problems can be targeted 
by drug repurposing where it improves the chances of success, shortens the testing 
time, and reduces the huge investment in cancer drug design and development.
Figure 1. 
Drug discovery and development with potential windows for drug repurposing.
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1.3  Opportunities for drug repositioning comes from path of drug discovery  
and development
The process of new drug designing and development involve many steps as 
mentioned in Figure 1. It may happen that Drug is serendipitously screened and 
found positive result for another disease. Gills et al. tested few anti-HIV drugs 
against many cancer cell lines using cytotoxicity assays. He found that nelfinavir has 
potent broad-spectrum antitumor activity [9]. Repurposing can also possible if new 
role discovered for an existing target. In case of metformin, the similar pathway of 
is found to be important in two different diseases like diabetes and cancer. It has 
been observed that unexpected side effects found during and after clinical trials 
show lead for drug repurposing like thalidomide for certain cancer.
2. Drug repositioning strategy
During preliminary screening on Drug, many possibilities of drug repurposing 
may arise by chance and later based on proper justification few of them have been 
tested for alternate application in another disease that called as shifting from bench 
to bedside. Oppositely, it may happen that unpredicted results of clinical trials sug-
gest ideas for drug repurposing and later same things justified by scientific experi-
ments that called as bedside to bench. According to FDA approved drug database, 
around 80–90% of drug gets failed in clinical trials due to various reasons and one 
of the majors is that the lack of efficacy during phase- III of clinical trial. That fail-
ure rate figures out around 30–50% and all these drugs might be good candidate for 
repurposing. The Figure 2 indicate different approaches that begin with construct-
ing hypothesis based on existing fund of knowledge to expanding its in silico frame 
work for preliminary testing and later on validating facts based on more vigorous 
and stringent analysis like preclinical and clinical studies [10].
3.  Necessity for drug repurposing in cancer treatment and availability of 
attractive candidates
Comparing cancer with other disease that takes much time to develop and working 
insidiously. Every cancer begins with few mutations that suppress tumor suppression 
gene and promoting oncogene that leads to abnormal cell proliferation, escape of 
apoptosis, immune evasion, inflammation, defects in DNA damage repair mechanism, 
Figure 2. 
Various approaches of drug repurposing.
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Warburg effects, angiogenesis and lack of differentiation of cell with most of the cells 
remain immature. As there is progress happen the picture of tumor microenvironment 
become more and more complicated. At this time tumor is no more homogenous but 
packed with heterogeneous cells and changing itself to more resistance form. The 
cancer might be supported by systemic condition of the body or in the other words 
internal anti-cancer mechanism become compromised to eradicate the tumor. The 
tumor microenvironment begins to secret many immunosuppressive cytokines and 
inflammatory mediators that sustain the tumor growth and save this corrupted cellular 
structure against honest immune system that work in the form of vigilance. After 
dominate at local region, tumor intrude to the other favorable region. Later on, metas-
tasis start based on seed and soil theory of Stephan Paget, where cancer cells work as 
“seeds” and the specific organ microenvironments work as “soil.” The success interac-
tion between these two entities determines the development of a secondary tumor [11].
After get metastasis, the most of the patients give response to first line treat-
ment not more than 50% for various cancers. At advance stages of cancer, majority 
of patients will develop anti-cancer resistance due to drastic abnormal genetic, 
epigenetic changes and surviving of cancer stem cells that not killed even after the 
death of tumor cells [12, 13]. So, it becomes important to repurpose drugs that able 
to act at multiple targets in tumors in patient that display genetic heterogeneity.
The following table (Table 1) consists of brief reviews of available good drug 
candidates for drug repurposing and some of that already approved.
Drug First approved target Approved in 
disease
Repurposed in cancer 
(preclinical/clinical)
Thalidomide [14] Might affect the 
medullary control centers 
(the vomiting center 
and the chemoreceptive 
trigger zone) or affect the 
peripheral receptors
Nausea, 
vomiting 
of pregnant 
woman (banned 
now)
Multiple myeloma by targeting 
TNF-α
Metformin [15] Activate the adenosine 
monophosphate activated 
protein kinase (AMPK) 
signaling pathway
Type-II diabetes 
mellitus
Mitochondrial respiration, 
reducing insulin and insulin-like 
growth factor levels, inhibits mTOR 
and activate p53, AMPK pathway
Everolimus [16] mTOR Immuno-
suppressant
In Pancreatic neuroendocrine by 
targeting mTOR signaling pathway
Trastuzumab [17] HER2 HER2-positive 
breast cancer
For HER2-positive metastatic 
gastric cancer
Aspirin (low dose;  
50–100 mg daily)
COX-1 Prevent Platelets 
aggregation in 
cardiovascular 
disease
Prostaglandin E2 (PGE2) decreased 
in colon cancer [18], inhibition of 
platelets to suppress NK cell-
mediated lysis of cancer cells [19]
Propranolol [20] β-receptor blocker Cardiovascular 
diseases
Reduced 57% risk of metastasis in 
Breast cancer by blocking cyclic 
AMP (cAMP), focal adhesion 
kinase (FAK)
Digoxin [21, 22] Na + -K + -ATPase Heart failure, to 
reduce heart rate
Rise in intracellular Na + and Ca2+ 
in human prostate adenocarcinoma 
cells, lead to activation of 
calcineurin and transcriptional 
upregulation of Fas ligand cause 
apoptosis. Also, suppression 
nuclear factor-kappa B and 
inhibition of DNA topoisomerase 
II are well documented.
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3.1 Various anti-cancer targets that can be used for repurposing of drug
Based on global statistics, more than 20 million individuals will be detected 
with cancer in 2025. Certain cancer like breast cancer, colorectal, prostate is mostly 
remaining incurable in advanced stages with existing treatment and that leads to 
increase in number of cases. Thus, addressing these present and future challenges 
requires more effective cancer drugs [29]. Traditional anti-cancer therapy like 
Chemotherapy and radiation have dangerous side effects that range from bone 
marrow suppression, oral mucositis, arising of secondary cancer to vomiting, diar-
rhea and organ specific toxicity that drastically decrease the quality life and overall 
survival of cancer patients [30]. From this point of view, drug repositioning option 
is promising strategy to identify non-cancer drugs like aspirin and chlorpromazine 
which have anti-tumor activity with less side effects comparable to traditional 
anti-cancer drugs. Traditionally limited targets were identified for anti-cancer 
drugs that involve cell cycle inhibitors, anti-metabolites, anti-angiogenesis, growth 
factor inhibitors, pro-apoptotic. But today many new targets identified that work 
in more specific way and reduce dangerous side effects of anti-cancers. Some novel 
drug target mentioned in following diagram that might be work well for future drug 
repurposing in oncotherapeutics (Figure 3).
Figure 3. 
Hall marks of cancer.
Drug First approved target Approved in 
disease
Repurposed in cancer 
(preclinical/clinical)
Chlorpromazine 
[19]
Dopamine receptor 
antagonist
In psychosis, 
bipolar disorder, 
schizophrenia
Increase in p21 [23], p51 expression 
[24]
Artemisinins Induce formation of 
reactive oxygen species 
(ROS) within the infected 
red blood cells (RBC)
Anti-malarial 
[25]
Anti-proliferative, pro-apoptotic 
effects [26]
Doxycycline Protein synthesis in 
bacteria
Antibiotics Down regulation of MMP-2 and 
MMP-9 expression in leukemia [27] 
and colorectal cancer cells [28]
Table 1. 
Repurposed drug for the cancer treatment.
Drug Repurposing
6
4. Methods for drug repurposing
It might be apparent that identifying specific drugs with pleiotropic effects is 
easy task but the execution is a complex. Following methods work well to reposi-
tioning of drug with the help of existing data, reducing the time of investigation, 
helping to reduce unnecessary animal experiments and regulatory obligations.
4.1 Computational methods
Although high through put screening (HTS) and many assay techniques available, 
it is difficult to predict drug and target interaction and its subsequence consequences 
[31]. Every drug bind with variety of targets but most of them attach with proteins 
that present in the form of receptors, ion channels, enzymes, antigen and transcrip-
tional factors [32]. To screen the drugs interaction with every of this target is not pos-
sible and also it consumes lots of time and money. Certain computational approaches 
are available that able to screen thousands of test drug molecule with many targets 
within short time period. The selection of drug and its possible targets are based on 
similarities based on structure, its protein binding and typical side effects that drugs 
produce [33–35]. Many molecular docking software are available that predict binding 
of drug molecule within active site of the target and able to predict the three-dimen-
sional interaction at atomic level. In this approach it is necessary to discover protein 
structures of both normal and disease condition to target it in proper way else bind-
ing of drug with normal protein structure may lead to side effects. Computational 
approach needs lots of information that can be derived from various databases and 
webservers like DrugBank [36], E medstore [37], KEGG: Kyoto Encyclopedia of 
Genes and Genomes [38], SuperTarget and Manually Annotated Targets and Drugs 
Online Resource (MATADOR) [39], Potential Drug Target Database (PDTD) [40], 
ZINC [41], CancerDR [42] and many others. Computational models broadly catego-
rized in to network based model that working based on the principles of multiple 
target optimal intervention (MTOI) [43], Drug side-effect similarity-based method 
[35] and machine learning-based model that further categorized into supervised 
learning method and semi-supervised learning method [32].
4.2 Biological experimental approaches
In this method the interaction in between drug and its target is determined. 
To accomplish this, we may fix the drugs on certain bead and allowing reaction of 
washing cell lysate extracts with drugs [44]. It is also possible to carry out high-
throughput screening based direct-binding assays to test drugs against certain 
kinases [45]. Cell based screening examine the evidence of autophagy, apoptosis 
or inhibition of proliferation in proper cell culture environment of different cancer 
cells [46–48]. Also, genetic expression study of drugs based on cell line can help in 
drug repurposing.
5. Drug repurposing database
Physical collection of approved drugs to carry out experimental repositioning 
screens is challenging task. Smaller digital libraries containing information of 
approved drugs or drugs with expired patents are available to serve drug repurpos-
ing like Enzi Life Sciences, Prestwick, Spectrum and many other like National 
Institute of Health’s Chemical Genomics Center (NCGC) [49]. It may happen that 
drug get failed in clinical trials because of lack of effectiveness (efficacy) but not 
due to toxicity represent good candidate for drug repositioning. There is some web 
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portal available that store large drug screening database based on clinical trials and 
can be used for repurposing.
• http://drugrepurposingportal.com
• CLUE: The Drug Repurposing Hub
Current status of drug repurposing based on drug and disease search option is 
available at repoDB site. This drug repositioning database contains information of 
about 2051 diseases, all mapped to UMLS terms for easier integration [50].
• http://apps.chiragjpgroup.org/repoDB/
6. Conclusion
The process of drug repurposing or repositioning help the Pharmaceutical 
companies in terms saving capital expenditure and decrease efforts of scientific 
community from long drug discovery and development process that pass through 
much experimental and regulatory task. Drug repositioning works well for those 
drug molecules for which disease targets are not get altered over a period of time. 
All the drug repositioning hypothesis will not transferred to successful outcome. 
It was happened with bevacizumab (Avastin), a kinase inhibitor drug that failed 
to prove its efficacy during phase- III of clinical trial in gastric cancer therapy 
although it has good efficacy against colon, rectal, brain, lung and kidney cancer 
by targeting vascular endothelial growth factor (VEGF) and decreasing the blood 
supply to the tumor that required for tumor growth and metastasis [51, 52]. Similar 
thing happened for sunitinib, a kinase inhibitor where it has proven its efficacy in 
certain cancers while unable to show same in other cancers [53]. It is significant to 
consider the unique drug indication during repositioning with proper justification 
for risk and benefits ratio. Any cytotoxic anti-cancer drug may not be an ideal drug 
for cardiovascular disorder in same dose, as it may kill many normal cells with high 
proliferation index. But it can be utilized at low doses for drug repurposing with 
less side effects as in the case of methotrexate at 10–20 mg per week for rheuma-
toid arthritis due to its anti-inflammatory property. Although, there are many 
obstacles present on the path of drug repurposing now, but future will bring more 
advancement in the technologies with the help of combinatorial chemistry, virtual 
screening, data mining and artificial intelligence that raise the success rates. At the 
last, we hope that all these scientific advancements translated into clinical setting 
to improve oncotherapy and reduce the burden of cancer related mortality in the 
world.
7. Future perspective
Tumor is heterogeneous mutated cell mass with genomic instability that 
acquired new forms over period of time. As time goes on, tumor heterogeneity 
environment become less vulnerable to chemotherapeutic and radiation agent with 
development of tumor resistance in multiple ways. So, every tumor shows different 
pathological picture in every cancer patient and even different pattern of intratu-
moural mutation in same patient at different time interval. Based of therapeutic 
modality, specific subpopulation of drug tolerant cancer cells come out as resistant 
cells within tumor. So, it seems personalized medicine will be future of Cancer 
medicines. In these regards, single cell analysis, multiple omics, research autopsy, 
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and sampling from multiple regions can help. Based on tumor heterogeneity and 
evolution of drug resistance point of view, the drug repurposing might be not 
evolved as unjustifiable tool with time consuming approach, if not utilized for early 
stages of Cancer patients.
Drug repurposing involves many challenges like proper utilization of database, 
demand of expected repurposing drug, issues associated with intellectual property 
rights and patents. Although to accomplish efficient drug repurposing, there is a 
need to work from multiple paradigms. Many drugs get failed in third phase of 
clinical trials and Drug repurposing trials due to lack of efficacy, so it should be 
realized in well advance by combining multiple techniques. Literature belongs to 
applied sciences and medical fields containing important information for comple-
mentary relationship in between repositioning of drugs and its proposed targets. 
The vital information can be extracted with “text mining” tools like Biovista, 
BioWisdom, TextFlow, DrugQuest, Polysearch, etc. Based on semantic integration 
network approach, diverse information can be interrelated. Later, many algo-
rithms in machine learning techniques can be developed to promote the efficacy 
and speed of drug repurposing. At present, multiple-omics discipline emerge out 
like genomics, proteomics, transcriptomics, bioinformatics, metabolomics and 
interactomics that consist of vast data related to biological sciences. Analyzing 
these multiple-omics disciplines with computational methods by integrative 
approach can be utilized to identify the best drug molecule that work at more than 
single target in different diseases. This approach may suit well with personalized 
medicine concept that will become inadvertent reality and demand in the case of 
oncotherapeutics. With these diverse but harmonizing computational with multi-
omics incorporation, scientist and researcher achieve meaningful understanding 
of cellular physiology, Drug -receptor interaction, pathogenesis and prognosis 
of diseases, stages and types of same disease with acquired changes at molecular 
level, possible drug reactions, on-target and off-target interactions, diagnostic and 
prognostic biomarkers.
According to WHO, Cancer is a leading cause of death worldwide, accounting 
for an estimated 9.6 million deaths in 2018. The most common causes of cancer 
death are cancers of lung (1.76 million deaths), colorectal (862,000 deaths), 
stomach (783,000 deaths), liver (782,000 deaths), and breast (627,000 deaths). 
Definitely at present scenario priority should be given for these cancers. There are 
many diseases are coming under the category of orphan disease. According to U. S. 
FDA, an orphan disease defined as a condition that affects fewer than 200,000 
people nationwide. There is good opportunity for repurposing to orphan drugs. 
According to Genetic and rare diseases (GARD) information center, many cancers 
comes under orphan diseases category like CDK4 linked melanoma (orphan drug 
Aldesleukin), carcinoid tumor (orphan drug Everolimus, Lutetium Lu 177 dot-
atate), chronic myeloid leukemia (orphan drug Bosutinib, Omacetaxine mepesuc-
cinate), clear cell renal cell carcinoma (orphan drug Sorafenib, Temsirolimus). 
These all orphan drugs that utilized for rare cancers are good candidates for Drug 
repurposing in other common types of cancer. Also, the drugs like thalidomide 
which was once withdraw from the market due to its dangerous teratogenic effects 
in one class of human population but later approved by FDA for myeloma and 
other disease treatment. The negative and positive sides of this drug are contrib-
uted by anti-angiogenesis property. But this one off-target property was proved 
to defame its efficacy in one situation while with Drug repurposing in other 
condition it has proved its anti-cancer effects. Future will become where more 
robust and sound techniques will be utilized to create successful Drug repurpos-
ing candidate and making drug discovery and development process beneficial to 
Human kind.
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